Blue Jet Healthcare reported a financial performance for FY26 characterized by strategic investments and mixed segmental results, with revenue from operations declining 8% to INR947 crores compared to the previous year. The company maintained a healthy profit after tax margin of 26% for the fiscal year, supported by other income of INR69 crores, which included an exchange gain of INR36 crores. Management emphasized that FY26 served as a foundational year for capacity expansion and R&D development, positioning the company for a transition into a commercialization and growth cycle in FY27.

Financial Performance

The company's revenue streams showed divergent trends during the year. The contrast media segment demonstrated strong momentum, with full-year revenue increasing 23% to INR495 crores. In Q4FY26, this segment reported revenue of INR193 crores, marking a 91% year-over-year increase. Conversely, the PI/API category faced significant challenges due to customer destocking, particularly for a cardiovascular drug intermediate, leading to a 35% decline in full-year revenue to INR298 crores. The artificial sweetener segment recorded a 2% drop in annual revenue to INR131 crores, though Q4 revenue rose 43% quarter-on-quarter to INR37 crores.

Strategic Expansion and Capex

Blue Jet Healthcare is executing a major capital expenditure plan to bolster its manufacturing capabilities. The company has commenced a greenfield expansion project in Vizag, spread across approximately 100 acres, with a total estimated investment of INR1,000 crores over three years. Phase 1 will focus on manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates. Additionally, the company is progressing with a backward integration project at its Mahad Unit 3 to strengthen supply chain reliability for contrast media. The total capital work in progress (CWIP) as of March 31, 2026, stood at INR301 crores.

Operational Outlook

Management indicated that the destocking impact in the PI segment has normalized, and the company is seeing improved order visibility as it enters FY27. The contrast media segment is expected to maintain positive momentum, driven by new product launches and existing customer partnerships. The company is also strengthening its R&D capabilities with a new center in Hyderabad, involving an investment of INR40 crores, focusing on newer chemistry platforms such as peptide-related intermediates and GLP-1 opportunities. Blue Jet Healthcare ended FY26 as a debt-free company with liquid financial assets of INR400 crores.

Blue Jet Healthcare Limited has scheduled an Extra-Ordinary General Meeting (EGM) on June 17, 2026, to seek shareholder approval for raising funds aggregating up to ₹10,000 million. The company proposes to issue securities, including fully paid-up Equity Shares, fully or partly convertible debentures, or other equity-linked instruments, through one or more tranches via preferential issues, private placements, or Qualified Institutions Placements (QIP).

The fundraising proceeds are intended for growing the existing business through product development, meeting long and short-term working capital requirements, funding capital expenditure, and pre-payment or repayment of outstanding borrowings. The board, at its meeting held on May 25, 2026, approved the proposal, which will be placed before shareholders as a special resolution. The company stated that the exact price, proportion, and timing of the issue will be determined by the board or a duly constituted committee in accordance with applicable regulations.

EGM and Voting Details

The EGM will be held on Wednesday, June 17, 2026, at 11:00 AM (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The remote e-voting period commences on June 14, 2026, at 9:00 AM and concludes on June 16, 2026, at 5:00 PM. Shareholders holding shares as on the cut-off date of June 10, 2026, are eligible to vote.

The notice specifies that if the issue is made through a QIP, the allotment of securities must be completed within 365 days from the date of passing the special resolution. The pricing of the securities will be determined in accordance with the pricing formula provided under Chapter VI of the SEBI ICDR Regulations, potentially including a discount of not more than 5% on the floor price. M/s. Mehta and Mehta, Company Secretaries, has been appointed as the scrutinizer for the e-voting process.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has intimated the exchanges regarding the publication of the EGM notice in newspapers, specifically the Financial Express (English) and Navshakti (Marathi). Sweta Poddar, Company Secretary and Compliance Officer, confirmed the dispatch of the notice on May 27, 2026.